OS THERAPIES INCORPORATED Cash and Restricted Cash
OS THERAPIES INCORPORATED (OSTX) had Cash and Restricted Cash of $205.03 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $205.03K.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $917.55K.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $269.83K.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.88M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $205.03K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $917.55K 10-Q · filed 2026-05-18 |
| 2025-12-31 | $269.83K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $1.88M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $2.80M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $2.97M 10-Q · filed 2026-05-18 |
| 2024-12-31 | $5.53M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $1.86M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $94.92K 10-Q · filed 2025-08-18 |
| 2024-03-31 | $100.23K 10-Q · filed 2025-05-15 |
| 2023-12-31 | $38.98K 10-K · filed 2026-03-31 |
| 2023-09-30 | $16.06K 10-Q · filed 2024-11-15 |
| 2023-06-30 | $49.22K 10-Q · filed 2024-08-14 |
| 2023-03-31 | $355.21K 10-Q · filed 2024-05-20 |
| 2022-12-31 | $171.48K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |